299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-002550-71-DE
(EUCTR)
12/09/201818/07/2018A clinical study to investigate safety, tolerability and dose of orally inhaled multiple doses of POL6014 in patients with Cystic FibrosisPhase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis Cystic Fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: POL6014
INN or Proposed INN: lonodelestat
Other descriptive name: CYCLO[L-ALANYL-L-SERYL-L-ISOLEUCYL-L-PROLYL-L-PROLYL-L-GLUTAMINYL-L-LYSYL-L-TYROSYL-D-PROLYL-L-PROLYL-(2S)-2-AMINODECANOYL-L-ALPHA-GLUTAMYL-L-THREONYL]
Santhera Pharmaceuticals (Switzerland) LtdNULLNot RecruitingFemale: yes
Male: yes
32Phase 1;Phase 2Germany
2NCT01051999
(ClinicalTrials.gov)
February 201015/1/2010Glutamine Supplementation in Cystic FibrosisGlutamine Supplementation and Immunity in Adults With Cystic FibrosisCystic Fibrosis;Immune FunctionDietary Supplement: Glutamine;Dietary Supplement: L-alanineEmory UniversityEmmaus Medical, Inc.Completed18 YearsN/ABoth17Phase 2United States
3EUCTR2007-006204-37-GB
(EUCTR)
03/07/200809/05/2008Glutamine supplementation for cystic fibrosis: a parallel group randomized controlled trial - Glutamine and CFGlutamine supplementation for cystic fibrosis: a parallel group randomized controlled trial - Glutamine and CF Cystic fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Product Name: Glutamine
Product Code: none
Other descriptive name: L-Glutamine
University of NottinghamNULLNot Recruiting Female: yes
Male: yes
44 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom